SCHEMBL206667

SCHEMBL206667

CCN(CCNC(=O)CCC(=O)NC1CCC(c2cccs2)(N(C)C)CC1)c1cccc(C)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.42
GAA P10253 1/20 0.42
GFER P55789 3/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 2/20 0.40
MAPT P10636 5/20 0.40
LMNA P02545 3/20 0.40
ALOX15 P16050 2/20 0.40
ALDH1A1 P00352 4/20 0.39
HTT P42858 3/20 0.39
HPGD P15428 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206795 0.87 OPRM1 (0.52) NPSR1GAAGFERCYP1A2CYP3A4
SCHEMBL208376 0.79 OPRM1 (0.44) KMT2AALDH1A1HPGDMEN1
SCHEMBL208543 0.79 OPRM1 (0.45) GAAGFERCYP3A4CYP2D6CYP2C19
SCHEMBL5160905 0.78 OPRM1 (0.42) NPSR1GAAGFERCYP1A2CYP3A4
SCHEMBL206686 0.76 KMT2A (0.42) CYP1A2CYP2D6CYP2C19KMT2ALMNA
SCHEMBL207133 0.76 ALDH1A1 (0.50) KMT2AMAPTALDH1A1HTTHPGD
SCHEMBL208760 0.76 SMYD3 (0.48) HTT
SCHEMBL4074077 0.76 OPRM1 (0.51) SMN1; SMN2
SCHEMBL206898 0.75 OPRM1 (0.60) CYP1A2CYP2C19LMNA
SCHEMBL210046 0.74 OPRM1 (0.46) KMT2AALOX15HPGDMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD NPSR1 3473/4885GAA 20/4885GFER 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.